The main advantage presented by autoCAR-T cells is the diminished risk of immune rejection (3). Donor T cells carry the potential risk of life-threatening Graft versus Host Disease (GvHD) (4). This is because allogeneic T cells may recognize the recipient's tissues as foreign due to human leukocyte antigen (HLA) disparities, triggering an immune response against the host cells. A clinical study observed that 21.4% of patients experiencing relapsed/refractory acute lymphoblastic leukemia (ALL) who underwent alloCAR-T therapy experienced acute GvHD .